Antithrombotic Effect of MCI-9042, a New Antiplatelet Agent on Experimental Thrombosis Models

Summary

The antithrombotic effect of MCI-9042, (±)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl] ethyl hydrogen succinate hydrochloride was investigated in three different experimental thrombosis models in animals. Simultaneous injection of serotonin and collagen into the tail vein in mice induced acute pulmonary thromboembolic death. MCI-9042 reduced the mortality in a dose dependent manner and its ED₅₀ value was 1.9 mg/kg po. Ticlopidine (TCP) which is a positive reference compound as an antithrombotic drug reduced the mortality at doses of 10 mg/kg po and above. Cyproheptadine (CPH) and ketanserin (KTS) which are S2-serotonergic antagonists were also effective on the reduction of mortality. In mesenteric arterial thrombosis induced by electric stimulation in mice, MCI-9042 prolonged the occlusion time resulted from platelet thrombus formation (PD₅₀: 23 mg/kg po). CPH and KTS prolonged the occlusion time as potent as MCI-9042, but TCP prolonged the occlusion time only at the high doses of 100 mg/kg po and above. In experimental arterial thrombosis which generated in implanted polyethylene tubing, MCI-9042 reduced the incidence of thrombus formation in the tubing and its ED₅₀ value was 18 mg/kg po. TCP was also effective in this model with an ED₅₀ of 170 mg/kg po. The present results lead to the consideration that serotonin plays a more important role in thrombus formation than that conjectured formerly, and suggest that MCI-9042 becomes a new kind of antithrombotic drug with S₂-serotonergic receptor antagonism.

• References

• 1 Kikumoto R, Hara H, Ninomiya K, Osakabe M, Sugano M, Fukami H, Tamao Y. Synthesis and platelet aggregation inhibitory and antithrombotic properties of (omega-aminoalkoxy)phenylethyl-benzenes. J Med Chem 1990; 33: 1818-23
• 2 Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. A novel anti-platelet agent, MCI-9042: A selective S₂-serotonergic antagonist. Thromb Haemostas 1989; 62: 407 (Abstr)
• 3 Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042: A new anti-platelet agent is a selective S₂-serotonergic receptor antagonist. Thromb Haemostas 1991; 65: 415-20
• 4 Komatsu T, Enjouji S, Nakai H, Inokuchi T, Iida S. Studies on the Metabolic fate of (±)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)-phenoxy]methyl]ethyl hydrogen succinate hydrochloride (MCI-9042) (II). Xenobio Metabol Dispos (in press)
• 5 Michiels M, Monbaliu J, Meuldermans W, Hendriks R, Geerts R, Woestenborghs R, Heykants J. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog. Arzneim Forsch 1988; 38: 775-84
• 6 Ashida S-I, Abiko Y. Inhibition of platelet aggregation by a new agent ticlopidine. Thromb Haemostas 1979; 40: 542-50
• 7 Tomikawa M, Ashida S-I, Kakihata K, Abiko Y. Anti-thrombotic action of ticlopidine a new platelet aggregation inhibitor. Thromb Res 1978; 12: 1157-64
• 8 Finney DJ. Probit Analysis. Cambrige University Press, London: 1961. pp 236-54
• 9 Lecker D, Kumar A. Effects of 6-[p-(4-phenylacetylpiperazin-l-yl)-phenyl]-4,5-dihydro-3 (2H)-pyridazinone (CCI-17810) and aspirin on experimental arterial thrombosis in rats. Thromb Haemostas 1980; 44: 9-11
• 10 Remy DC, Raab AW, Rittle KE, Engelhartdt EL, Scriabine A, Lotti VJ. A comparison of the anti serotonin anti histamine and anti cholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10,11 vinylene bridge. J Med Chem 1977; 20: 836-8
• 11 Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM. Vascular effects of ketanserin (R41468), a novel antagonist of 5-HT₂ serotonergic receptors. J Pharmacol Exp Ther 1981; 218: 217-30
• 12 Duval DL, Didisheim P, Titus JL, Spittell JA, Owen CA. Experimental arterial thrombosis: Description of a method. Mayo Clin Proc 1970; 45: 388-95
• 13 Hladovec J. The effect of some platelet aggregating and potential thrombosis-promoting substances on the development of experimental arterial thrombosis. Thromb Diathes Haemorrh 1973; 29: 196-200
• 14 Bush LR, Cambell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT. The effects of a₂-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 1984; 55: 642-52
• 15 Bush LR. Effect of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries. J Pharmacol Exp Ther 1987; 240: 674-82
• 16 Aiken JW, Goram RR, Shebusli RJ. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlated with inhibition of platelet aggregation. Prostaglandins 1979; 17: 483-94
• 17 Folts JD, Gallagher KB, Rowe GG. Blood flow reduction in stenosed canine coronary arteries: Vasospasm or platelet aggregation?. Circulation 1982; 65: 248-54
• 18 Bush LR, Cambell WB, Buja LM, Tilton GF, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984; 69: 1161-70
• 19 Aiken JW. Pharmacological analysis of factors influencing platelet aggregation in stenosed coronary arteries of dogs. Ann N Y Acad Sci 1985; 454: 131-4
• 20 Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988; 78: 701-11
• 21 Golino P, Ashton JH, Buja LM, Rosolowsky M, Taylor AL, McNatt J, Cambell WB, Willerson JT. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Circulation 1989; 79: 154-66
• 22 Hladovec J. The effect of antithrombotics in a new model of arterial thrombosis. Thromb Res 1986; 41: 665-70
• 23 Bekemeier H, Hirschelmann R, Giessler AJ. Carrageenin-induced thrombosis in rats and mice: A model for testing antithrombotic substances?. Agents Actions 1985; 16: 446-51
• 24 Bekemeier H, Hirschelmann R. Influence of serotonin, serotonin antagonists, some vasoactive substances and temperature on carrageenin-induced tail thrombosis in rats and mice. Agents Actions 1986; 18: 581-5
• 25 Shih HC. Pharmacological studies on selective serotonin-S₂ antagonist antihypertensive effect of ketanserin and effects of the central nervous system. J Tokyo Med Coll 1988; 46: 851-61
• 26 McGoutry JC, Silas JH, Cowen KJ. Controlled trial of ketanserin in hypertension. Br J Clin Pharmacol 1985; 20: 37-40
• 27 Loux JJ, Smith S, Salem H. Comparative analgetic testing of various compounds in mice using writhing techniques. Arzneim Forsch 1978; 28: 1644-7